Página 1 dos resultados de 16 itens digitais encontrados em 0.004 segundos

Atitude do consumidor frente à propaganda: um estudo sobre os apelos racionais e emocionais da propaganda na indústria farmacêutica; Consumer's attitude toward advertising: a study about rational and emotional appeals in pharmaceutical industry ads

Huertas, Melby Karina Zúñiga
Fonte: Biblioteca Digitais de Teses e Dissertações da USP Publicador: Biblioteca Digitais de Teses e Dissertações da USP
Tipo: Tese de Doutorado Formato: application/pdf
Publicado em 28/11/2005 PT
Relevância na Pesquisa
46.68%
Diante de discrepâncias na literatura sobre a recomendação de alguns modelos de propaganda de se emparelhar os apelos (racionais ou emocionais) à atitude do consumidor sobre o produto (predominantemente cognitiva ou predominantemente afetiva), o objetivo geral desta Tese foi avaliar tal recomendação. A revisão bibliográfica evidenciou algumas lacunas teóricas: 1) generalização indevida de resultados de estudos sobre formatos de propaganda para produtos de outras categorias; 2) não mensuração direta dos componentes cognitivo e afetivo da atitude do consumidor nos modelos de propaganda, que consideram apenas o tipo de necessidade que o produto satisfaz e o envolvimento do consumidor como determinante da atitude sobre o produto; 3) não consideração de outras características do consumidor, além do envolvimento, como determinante da atitude nos modelos de propaganda; 4) ausência da atitude do consumidor sobre o produto dentre os antecedentes da atitude do consumidor frente a anúncio. Procurando superar tais deficiências, foi empreendida pesquisa de campo contemplando: a) uma categoria de produto específica (medicamentos / medicamentos para emagrecer); b) a mensuração dos componentes cognitivo e afetivo da atitude; c) a avaliação de outras características do consumidor (estado de saúde / peso e experiência com o produto) que influenciam sua atitude; d) atitude do consumidor sobre o produto como possível antecedente da atitude dele frente a anúncio. A pesquisa empírica consistiu de três etapas. A primeira...

Eliminating barriers to DTC advertising for OTCs and natural health products

Kondro, Wayne
Fonte: Canadian Medical Association Publicador: Canadian Medical Association
Tipo: Artigo de Revista Científica
Publicado em 23/05/2006 EN
Relevância na Pesquisa
26.18%

DTC Advertising: Where Do Genetic Tests Fit?

Carlson, Bob
Fonte: BioCommunications LLC Publicador: BioCommunications LLC
Tipo: Artigo de Revista Científica
Publicado em /04/2009 EN
Relevância na Pesquisa
26.18%

C-B3-04: Media Analysis of Genetic Testing Information for Common Disease Presented to the Public

Rahm, Alanna Kulchak
Fonte: Marshfield Clinic Publicador: Marshfield Clinic
Tipo: Artigo de Revista Científica
Publicado em /03/2010 EN
Relevância na Pesquisa
26.58%
Background/Aims: With the advent of personalized medicine, consumers are routinely exposed to information and direct- to- consumer (DTC) advertising of various genetic tests. Specifically, 2007–2008 saw a return of the DTC advertisement for BRACAnalysis® in the eastern US, and the advent of three new companies offering DTC genetic screening for under $1000. This abstract presents the results of a media analysis for information presented to the general public on genetic testing for common diseases, such as cancer or heart disease, or for full genome scans for disease risk in general.

Statement of the ESHG on direct-to-consumer genetic testing for health-related purposes

Fonte: Nature Publishing Group Publicador: Nature Publishing Group
Tipo: Artigo de Revista Científica
EN
Relevância na Pesquisa
16.44%
Many private companies offer direct-to-consumer (DTC) genetic testing services. Some tests may detect severe and highly penetrant monogenic disorders, while other tests are for genetic variants found associated with increased susceptibility for common and complex diseases in large-scale population studies. Through its Public and Professional Policy committee followed by member and expert consultation, the European Society of Human Genetics has developed the following policy on advertising and provision of predictive genetic tests by such DTC companies: (1) clinical utility of a genetic test shall be an essential criterion for deciding to offer this test to a person or a group of persons; (2) laboratories providing genetic tests should comply with accepted quality standards, including those regarding laboratory personnel qualifications; (3) information about the purpose and appropriateness of testing should be given before the test is done; (4) genetic counselling appropriate to the type of test and disease should be offered; and for some tests psychosocial evaluation and follow-up should be available; (5) privacy and confidentiality of sensitive genetic information should be secured and the data safely guarded; (6) special measures should be taken to avoid inappropriate testing of minors and other legally incapacitated persons; (7) all claims regarding genetic tests should be transparent; advertisement should be unbiased and marketing of genetic tests should be fair; (8) in biomedical research...

PS1-09: Public Opinion of Family History and Genetic Testing for Common Diseases: Results from Focus Groups with Kaiser Permanente Colorado Members

Rahm, Alanna Kulchak
Fonte: Marshfield Clinic Publicador: Marshfield Clinic
Tipo: Artigo de Revista Científica
Publicado em /12/2010 EN
Relevância na Pesquisa
26.44%
Background and Aims: With the advent of personalized medicine, consumers are routinely exposed to information about new gene discoveries, family history, and direct-to-consumer (DTC) advertising of genetic tests. Since 2008, the BRACAnalsysis® test for breast cancer risk has been steadily advertised directly to consumers in different markets across the US, and at least 3 companies now offer DTC genetic screening for $300 – $1000, with more companies entering this burgeoning market. The specific aims of this project are to:

Is there a doctor in the house?: The presence of physicians in the direct-to-consumer genetic testing context

Howard, Heidi Carmen; Borry, Pascal
Fonte: Springer-Verlag Publicador: Springer-Verlag
Tipo: Artigo de Revista Científica
EN
Relevância na Pesquisa
16.72%
Over the last couple of years, many commercial companies, the majority of which are based in the USA, have been advertising and offering direct-to-consumer (DTC) genetic testing services outside of the established health care system, and often without any involvement from a health care professional. In the last year, however, a number of DTC genetic testing companies have changed their provision model such that consumers must now contact a health care professional before being able to order the genetic testing service. In discussing the advent of this new model of service provision, this article also reviews the ethical and social issues surrounding DTC genetic testing and addresses the potential motivations for change, some barriers to achieving truly appropriate medical supervision and the present reality of DTC genetic testing for some psychiatric and neurological disorders. Since the advent of these commercial activities, critics have pointed a finger at the lack of medical supervision surrounding these services. The discussion herein, however, reveals how difficult it may be, despite the addition of a physician, to actually achieve adequate medical supervision within the present context of DTC genetic testing.

American Exceptionalism and Direct-to-Consumer Advertising: Structural and Philosophical Impediments to Reform in Europe

Trento, Andrea W.
Fonte: Harvard University Publicador: Harvard University
Tipo: Paper (for course/seminar/workshop)
EN_US
Relevância na Pesquisa
47.08%
Despite a recent EC Proposal to relax its prohibition on direct-to-consumer (DTC) advertising of prescription drugs in certain, limited contexts, the prospects for broader reform in Europe on this issue are extremely grim. This essay argues that fundamental structural and philosophical differences in health care administration between the United States and Europe bode ill for the further relaxation of the prohibition in Europe. After exploring the causes and consequences of the emergence of DTC advertising in the United States, the essay examines the likelihood that a similar constellation of factors might align in Europe to produce similar results, concluding that the particular differences between the US and European systems render harmonization on this issue highly unlikely. Nevertheless, drawing on criticisms of the practice of DTC advertising in the United States, the essay notes that Europeans’ emphasis on deference to the expertise of the physician would vitiate some of the problems associated with DTC advertising in the United States.

DTC Prescription Drug Advertising: The History and Impact of FDA Regulation

Hartgraves, Tiffany
Fonte: Harvard University Publicador: Harvard University
Tipo: Paper (for course/seminar/workshop)
EN_US
Relevância na Pesquisa
57.14%
This paper traces the history of direct-to-consumer (DTC) advertising for prescription drugs in the United States, beginning with the enactment of the Federal Food, Drug, and Cosmetics Act in 1938 and continuing through the current state of FDA regulation. A detailed analysis of how the promulgation of DTC ads has affected a variety of groups (including consumers, the medical profession, pharmaceutical companies, the government, and advertisers) is followed by a brief look at a well-known DTC ad campaign (Schering-Plough’s Claritin). The paper questions whether DTC ads are a constructive or a deconstructive element of the American healthcare system and concludes by offering an opinion on the current state of DTC advertising regulation and enforcement by the FDA.

Direct-to-Consumer Advertising of Alzheimer’s Disease Drugs

Arakawa, Chika
Fonte: Harvard University Publicador: Harvard University
Tipo: Paper (for course/seminar/workshop)
Relevância na Pesquisa
37.05%
Use of direct-to-consumer (DTC) advertising by pharmaceutical manufacturers has skyrocketed in the past few decades as patients demand more information on drugs and the FDA has gotten more relaxed in its regulation of such marketing. In particular, television advertisements for prescription drugs for chronic conditions have dramatically increased. This paper will analyze the use of DTC advertising for prescription drugs for Alzheimer’s disease, a debilitating disease which can last for more than a decade before it leads to death. The paper will start with a history of DTC advertising and the FDA’s regulation of such advertisements. It will then proceed to analyze issues of DTC advertising which are particularly pertinent for Alzheimer’s disease, with an in-depth look at Aricept, one FDA-approved drug for Alzheimer’s. The paper will conclude with suggestions for further studies in the area and a number of proposals for reform.

Apelos racionais e emocionais na propaganda de medicamentos de prescrição: estudo de um remédio para emagrecer; Rational and emotional appeals in prescription drug advertising: study of a weight loss drug

HUERTAS, Melby Karina Zuniga; CAMPOMAR, Marcos Cortez
Fonte: Associação Brasileira de Pós-Graduação em Saúde Coletiva Publicador: Associação Brasileira de Pós-Graduação em Saúde Coletiva
Tipo: Artigo de Revista Científica
POR
Relevância na Pesquisa
46.99%
A propaganda Direta ao Consumidor (DC) de medicamentos encoraja as pessoas a perguntar aos médicos por determinados medicamentos e tratamentos que requerem prescrição médica. Para aumentar o poder persuasivo, modelos de propaganda recomendam equiparar os apelos (racionais e/ou emocionais) à atitude do consumidor sobre o produto (cognitiva e/ou afetiva). Essa recomendação gera controvérsias no âmbito da propaganda DC. Apelos emocionais seriam sempre inadequados, embora freqüentemente utilizados, nesse tipo de propaganda. Devido à inexistência de evidência empírica sobre a perspectiva do consumidor, empreendeu-se um levantamento descritivo com objetivo de avaliar: i) os componentes da atitude sobre medicamentos; ii) a atitude e as intenções comportamentais frente a anúncios DC (um com apelos racionais e outro com apelos emocionais). Escolheu-se um medicamento de prescrição para emagrecer. Constatou-se atitude predominantemente cognitiva sobre o produto e atitude e intenção comportamental mais favorável frente a anúncio racional. Cognição negativa sobre o produto foi marcante, anulando o poder persuasivo de apelos emocionais.; The Direct-to-Consumer (DTC) advertising of medicines encourages people to ask doctors for certain medicines and treatments that require medical prescription. In order to enhance their persuasive power...

Federal Preemption in the Area of Direct-to-Consumer (DTC) Advertising of Prescription Drugs

Blickle, Carl J.
Fonte: Harvard University Publicador: Harvard University
Tipo: Paper (for course/seminar/workshop)
EN_US
Relevância na Pesquisa
56.99%
FDA involvement in the policy space of direct-to-consumer (DTC) advertising of prescription drugs raises the question whether state-law based lawsuits based on such advertising are preempted. Congress and the Supreme Court have not provided helpful guidance. The FDA has recently taken an aggressive stance favoring preemption. The lower courts that have considered the issue in areas of (1) failure-to-warn claims, (2) fraud and false advertising claims, and (3) claims for specific relief. The lower courts have reached mixed results, though the majority seem to disfavor preemption. This paper argues that, for a variety of reasons, most state-law based claims founded on DTC advertising should be preempted under either "implied" preemption doctrine or as obstacles to the FDA's program of encouraging optimal drug use.

PEREZ v. WYETH LABORATORIES INC. & THE WISDOM OF AN ADVERTISING EXCEPTION TO THE LEARNED INTERMEDIARY RULE

Piranian, Heidi
Fonte: Harvard University Publicador: Harvard University
Tipo: Paper (for course/seminar/workshop)
EN_US
Relevância na Pesquisa
46.96%
On August 9, 1999, the Supreme Court of New Jersey issued the first high-level court opinion to recognize a direct-to-consumer ("DTC") advertising exception to the learned intermediary rule. Although the manufacturer in Perez v. Wyeth Lab. Inc. had satisfied its duty to provide medical professionals with full warnings, the court held that the usual protection offered by the learned intermediary rule was not automatically available since the manufacturer had engaged in DTC advertising. Because the manufacturer's advertising campaign on television and in women's magazines had failed to warn of certain side effects and complications attendant to removal of its Norplant implants, the court held that the question of whether inadequate warnings constituted proximate cause should be submitted to a jury.

HIDDEN in PLAIN SIGHT Marketing Prescription Drugs to Consumers in the Twentieth Century

Greene, Jeremy A.; Herzberg, David
Fonte: American Public Health Association Publicador: American Public Health Association
Tipo: Artigo de Revista Científica
Publicado em /05/2010 EN
Relevância na Pesquisa
16.73%
Although the public health impact of direct-to-consumer (DTC) pharmaceutical advertising remains a subject of great controversy, such promotion is typically understood as a recent phenomenon permitted only by changes in federal regulation of print and broadcast advertising over the past two decades. But today's omnipresent ads are only the most recent chapter in a longer history of DTC pharmaceutical promotion (including the ghostwriting of popular articles, organization of public-relations events, and implicit advertising of products to consumers) stretching back over the twentieth century. We use trade literature and archival materials to examine the continuity of efforts to promote prescription drugs to consumers and to better grapple with the public health significance of contemporary pharmaceutical marketing practices.

Health care providers and direct-to-consumer access and advertising of genetic testing in the United States

Myers, Melanie F
Fonte: BioMed Central Publicador: BioMed Central
Tipo: Artigo de Revista Científica
Publicado em 28/12/2011 EN
Relevância na Pesquisa
36.86%
Marketing pressures, regulatory policies, clinical guidelines, and consumer demand all affect health care providers' knowledge and use of health-related genetic tests that are sold and/or advertised to consumers. In addition, clinical guidelines, regulatory policies, and educational efforts are needed to promote the informed use of genetic tests that are sold and advertised to consumers and health care providers. A shift in culture regarding the regulation of genetic tests that are sold directly to consumers is suggested: by recent actions taken by the US Food and Drug Administration (FDA), including letters sent to direct-to-consumer (DTC) genetic testing companies stating that their tests meet the definition of medical devices; by public meetings held by the FDA to discuss laboratory developed tests; and by the convening of the Molecular and Clinical Genetics Panel to gather input on scientific issues concerning DTC genetic tests that make medical claims. This review provides a brief overview of DTC advertising and the regulation of pharmaceuticals and genetic tests in the United States. It highlights recent changes in the regulatory culture regarding genetic tests that are sold to consumers, and discusses the impact on health care providers of selling and advertising genetic tests directly to consumers.

"For the good of the patient," survey of the physicians of the National Medical Association regarding perceptions of DTC advertising, Part II, 2006.

Morris, Albert W.; Gadson, Sandra L.; Burroughs, Valentine
Fonte: National Medical Association Publicador: National Medical Association
Tipo: Artigo de Revista Científica
Publicado em /03/2007 EN
Relevância na Pesquisa
47.32%
BACKGROUND: Since the advent of direct-to-consumer (DTC) advertising in the 1980s, there have been numerous studies and surveys on the topic, addressing issues as varied as its impact on patient understanding of health conditions to its repercussions for drug spending. However, until 2001, there was a dearth of research on DTC advertising's impact on minority populations, specifically the African-American community. The National Medical Association (NMA) remedied that in 2001 by undertaking a landmark study that gauged African-American physicians' perceptions of DTC advertising, its impact on the doctor-patient relationship and, perhaps most importantly, its role in educating underserved populations about critical health issues and potential treatments. In 2006, the NMA decided to once again poll its members on this critical issue to gauge not only current perceptions but how the community's understanding of DTC advertising has changed since 2001. RESULTS: The 2006 survey revealed several clear trends: NMA physicians are more positive toward DTC advertising now than they were in 2001; African-American physicians see DTC advertising as providing substantial educational benefits; physicians believe that DTC advertising helps rather than hurts the doctor-patient relationship; and African-American physicians see the benefits of DTC advertising outweighing its drawbacks. It must be noted that NMA physicians also had clear concerns about DTC advertising that point to potential areas of improvement for pharmaceutical companies.